• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡非佐米相关血栓性微血管病最初采用治疗性血浆置换进行治疗。

Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.

作者信息

Sullivan Matthew R, Danilov Alexey V, Lansigan Frederick, Dunbar Nancy M

机构信息

Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.

Department of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.

出版信息

J Clin Apher. 2015 Oct;30(5):308-10. doi: 10.1002/jca.21371. Epub 2014 Nov 21.

DOI:10.1002/jca.21371
PMID:25413611
Abstract

Drug associated thrombotic microangiopathy (TMA) is a rare event causing thrombocytopenia, microangiopathic anemia, renal failure, and neurologic abnormalities. Here, we present a case of TMA that occurred during the first cycle of treatment with carfilzomib for relapsed multiple myeloma.

摘要

药物相关血栓性微血管病（TMA）是一种罕见的病症，可导致血小板减少、微血管病性贫血、肾衰竭和神经功能异常。在此，我们报告一例在使用卡非佐米治疗复发多发性骨髓瘤的首个疗程中发生的TMA病例。

相似文献

1
Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.卡非佐米相关血栓性微血管病最初采用治疗性血浆置换进行治疗。
J Clin Apher. 2015 Oct;30(5):308-10. doi: 10.1002/jca.21371. Epub 2014 Nov 21.
2
Carfilzomib: A cause of drug associated thrombotic microangiopathy.卡非佐米：药物相关性血栓性微血管病的一个病因。
Transfus Apher Sci. 2016 Jun;54(3):401-4. doi: 10.1016/j.transci.2016.03.002. Epub 2016 Mar 15.
3
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.一名多发性骨髓瘤患者使用卡非佐米后出现的肾血栓性微血管病和足细胞病
BMC Nephrol. 2014 Sep 30;15:156. doi: 10.1186/1471-2369-15-156.
4
Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.多发性骨髓瘤中的微血管病：一例因卡非佐米引起的继发性血栓性微血管病，经血浆置换和补体抑制成功治疗。
BMC Nephrol. 2023 Jun 19;24(1):179. doi: 10.1186/s12882-023-03228-9.
5
[Not Available].[无可用内容]
Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163.
6
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.补体作为卡非佐米诱导的血栓性微血管病的促成因素。
Br J Haematol. 2021 Apr;193(1):181-187. doi: 10.1111/bjh.16796. Epub 2020 May 29.
7
Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.卡非佐米诱导的血栓性微血管病：基于病例的综述。
Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):426-431. doi: 10.1016/j.hemonc.2020.07.001.
8
Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.卡非佐米诱导的溶血较为常见，但很少出现血栓性微血管病的特征：一项回顾性研究。
Eur J Haematol. 2020 Jun;104(6):588-593. doi: 10.1111/ejh.13401. Epub 2020 Mar 15.
9
A review of thrombotic microangiopathies in multiple myeloma.多发性骨髓瘤中的血栓性微血管病综述。
Leuk Res. 2019 Oct;85:106195. doi: 10.1016/j.leukres.2019.106195. Epub 2019 Jul 29.
10
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.药物性血栓性微血管病合并蛋白酶体抑制剂用于治疗多发性骨髓瘤：病例系列及文献综述
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e791-e800. doi: 10.1016/j.clml.2020.04.014. Epub 2020 Apr 30.

引用本文的文献

1
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.蛋白酶体抑制剂相关血栓性微血管病：一项真实世界回顾性和药物警戒数据库分析。
Support Care Cancer. 2025 Feb 13;33(3):184. doi: 10.1007/s00520-025-09219-w.
2
Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review.多发性骨髓瘤患者长期使用卡非佐米治疗后血栓性微血管病（TMA）延迟发作：病例报告及综述
Pharmaceuticals (Basel). 2024 Dec 20;17(12):1722. doi: 10.3390/ph17121722.
3
[Not Available].
[无可用内容]
Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163.
4
Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.2例多发性骨髓瘤患者同时发生卡非佐米诱导的血栓性微血管病
Fed Pract. 2022 Aug;39(Suppl 3):S56-S62. doi: 10.12788/fp.0284. Epub 2022 Jun 16.
5
Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone.盐皮质激素受体途径是卡非佐米诱导肾毒性的关键介质：依普利酮的预防作用。
Hemasphere. 2022 Oct 18;6(11):e791. doi: 10.1097/HS9.0000000000000791. eCollection 2022 Nov.
6
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.卡非佐米诱导的血栓性微血管病：聚焦发病机制
J Med Cases. 2022 Jun;13(6):274-280. doi: 10.14740/jmc3932. Epub 2022 Jun 11.
7
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.与对照组相比，卡非佐米诱导的血栓性微血管病多发性骨髓瘤患者补体失调的遗传和功能证据
J Clin Med. 2022 Jun 10;11(12):3355. doi: 10.3390/jcm11123355.
8
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.在CARDAMON研究中，接受卡非佐米、环磷酰胺和地塞米松治疗的未治疗骨髓瘤患者中的血栓性微血管病。
Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1.
9
Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.卡非佐米诱导的不典型溶血性尿毒症综合征：诊断挑战与治疗成功案例
BMJ Case Rep. 2021 Feb 26;14(2):e239091. doi: 10.1136/bcr-2020-239091.
10
Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.小儿肿瘤肾脏病学：是时候广而告之了：第一部分：恶性肿瘤患儿的早期肾脏受累情况
Pediatr Nephrol. 2021 Aug;36(8):2227-2255. doi: 10.1007/s00467-020-04800-3. Epub 2020 Nov 27.